1
8
H.F.A. El-Halim et al. / Spectrochimica Acta Part A 82 (2011) 8–19
1
.2
1
C = 0
C = 5
C = 12.5
C = 25
C = 50
0
0
0
0
.8
.6
.4
.2
0
LFX
Mn(II)
Co(II)
Ni(II)
Cu(II)
Zn(II)
Fig. 4. The anticancer activity of LFX and its binary complexes.
chelation theory [48]. The orbital of each metal ion is made so as
to overlap with the ligand orbital. Increased activity enhances the
lipophilicity of complexes due to delocalization of pi-electrons in
the chelate ring [46]. In some cases increased lipophilicity leads to
breakdown of the permeability barrier of the cell [44,48,49].
gal activity tests were performed using the disc diffusion method.
Also the anticancer activity against breast cancer cell line (MCF7)
was also studied. The complexes show a remarkable biological and
anticancer activity.
Appendix A. Supplementary data
3.14.1.2. Cytotoxic activity
The LFX drug and its metal complexes were tested for their
activity against breast cancer cell line (MCF7) by using 100 g/ml
concentration. From these result summarized in Table 5), it
is clear that LFX, [Mn(LFX)(H O) ]·Cl , [Co(LFX)(H O) ]·Cl
2
4
2
2
4
2,
[
[
Ni(LFX)(H O) ]Cl ·H O,
[Cu(LFX)(H O) ]Cl ·2H O
and
References
2
4
2
2
2
4
2
2
Zn(LFX)(H O) ]·Cl were found to be very active against breast
2
4
2
[
[
[
1] www.drugbank.ca.
cancer cells with inhibition ratio values between 70–85.5%, while
other complexes utilized in this work had been shown to be
inactive (less than 70% inhibition). The pattern of activity can be
determined using different drug concentrations (Table 5). LFX,
2] I. Turel, Coord. Chem. Rev 232 (2002) 27–47.
3] Y. Xia, Z.Y. Yang, S.L. Morrisnatschke, K.H. Lee, Curr. Med. Chem 6 (1999)
179–194.
[
4] A.D. da Silva, M.V. de Almeida, M.V.N. de Souza, M.R.C. Couri, Curr. Med. Chem.
10 (2003) 21–39.
[
Co(LFX)(H O) ]·Cl and [Zn(LFX)(H O) ]·Cl were found to be
2
4
2
2
4
2
[
5] M.V.N. de Souza, Mini-Rev. Med. Chem. 5 (2005) 1009–1017.
very active with IC50 values 14, 11.2 and 43.1, respectively, while
other complexes are found to be inactive at lower concentration
than 100 g/ml (Fig. 4).
[6] G. Anquetin, J. Greiner, N. Mahmoud, M.S. Hayat, R. Gozalbes, K. Farhati, F. Der-
ouin, A. Aubry, E. Cambau, P. Vierling, Eur. J. Med. Chem. 41 (2006) 1478–1493.
[
[
[
7] M. Ruiz, R. Ortiz, L. Perello, S. Garcıa-Granda, M.R. Dıaz, Inorg. Chim. Acta 217
(
1994) 149–154.
8] M. Ruiz, L. Perello, J. Server-Carrio, R. Ortiz, S. Garcıa-Granda, M.R. Diaz, E.
Canton, J. Inorg. Biochem. 69 (1998) 231–239.
9] B. Macias, M.V. Villa, M. Sastre, A. Castineiras, J. Borras. J. Pharm. Sci. 91 (2002)
4
. Conclusion
2
416–2423.
In the present paper, the data obtained from elemental analysis,
[
10] Z.H. Chohan, C.T. Supuran, A. Scozzafava, J. Enzyme Inhib. Med. Chem. 20 (2005)
303–307.
FT-IR, electronic absorption spectra, thermal analyses, molar con-
ductivities and magnetic susceptibility measurements show that
the complexes of Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II),
[11] Z.H. Chohan, H. Pervez, A. Rauf, C.T. Supuran, Met. Based Drugs 8 (2001)
63–267.
2
[
12] M.P. Lopez-Gresa, R. Ortiz, L. Perello, J. Latorre, M. Liu-Gonzalez, S. Garcıa-
Granda, M. Perez-Priede, E. Canton, J. Inorg. Biochem. 92 (2002) 65–74.
UO (II) and Th(IV) metal ions with the investigated LFX drug may be
2
formulated, where bonding in 1:1 complexes are formed through
coordination with oxygen of the carbonyl group and protonated
carboxylic O group. The complexes obtained contain water of coor-
dination in their sphere. The investigated LFX drug acts as neutral
bidentate ligand. The solid complexes prepared behave as elec-
trolytes in DMF solution. The diffused reflectance spectra of the
investigated complexes together with the magnetic moment mea-
surements support the octahedral geometry. The complexes also
exhibit M to L charge transfer spectra. The bands observed at higher
wavenumbers which are not observed in the spectrum of the free
LFX ligand may be ascribed to d–d electronic transition within the
metal ions.
[13] J.R. Anacona, C. Toledo, Trans. Met. Chem. 26 (2001) 228–231.
[14] I. Turel, L. Golic, P. Bukovec, M. Gubina, J. Inorg. Biochem. 71 (1998) 53–60.
[15] I. Turel, I. Leban, N. Bukovec, J. Inorg. Biochem. 66 (1997) 241–245.
[16] F. Gao, P. Yang, J. Xie, H. Wang, J. Inorg. Biochem. 60 (1995) 61–67.
[17] S. Jain, N.K. Jain, K.S. Pitre, J. Pharm. Biomed. Anal. 29 (2002) 795–801.
[
18] D.K. Saha, S. Padhye, C.E. Anson, A.K. Powell, Inorg. Chem. Commun. 5 (2002)
022–1027.
19] H. Beraldo, D. Gambino, Mini Rev. Med. Chem. 4 (2004) 31–39.
1
[
[20] C. Chulvi, M.C. Munoz, L. Perello, R. Ortiz, M.I. Arriortua, J. Via, K. Urtiaga, J.M.
Amigo, L.E. Ochando, J. Inorg. Biochem. 42 (1991) 133–138.
[
21] M. Ruiz, R. Ortiz, L. Perello ˇı , A. Castin˜eiras, M. Quiro ˇı s, Inorg. Chim. Acta 211
1993) 133–139.
[22] Z.F. Chen, R.G. Xiong, J. Zhang, X.T. Chen, Z.L. Xue, X.Z. You, Inorg. Chem. 40
2001) 4075.
(
(
[
23] M.S. Refat, G.G. Mohamed, R.F. de Farias, A.K. Powell, M.S. El-Garib, S.A. El-
Korashy, M.A. Hussien, J. Therm. Anal. Calor. 102 (2010) 225–232.
The dissociation constants of lomefloxacin and stability
constants of its binary complexes have been determined spec-
[24] M.S. Refat, G.G. Mohamed, J. Chem. Eng. Data 55 (2010) 3239–3246.
[25] I.M. Issa, R.M. Issa, M.R. Mahmoud, Y.M.Z. Temerk, Physik. Chem. 254 (1973)
314–318.
◦
trophotometrically in aqueous solution at 25 ± 1 C and at 0.1 M
[
26] I. Sakiyan, E. Logoglu, S. Arslan, N. Sari, Bio. Met. 17 (2004) 115–120.
KNO ionic strength. Calculation of formation constants has evi-
[27] P. Skehan, R. Storeng, J. Natl. Cancer Inst. 42 (1990) 1107–1112.
[28] M.M. Abd-Elzaher, J. Chin. Chem. Soc. 48 (2001) 153–158.
3
denced its strong affinity towards metal cations. Also, the % metal
ion content (Suppl. Table 1) as well as the TG data (Table 2) are
concordant with the mononuclear structure (Fig. 2). From the inter-
pretation of elemental and thermal analyses and spectral studies as
well as magnetic susceptibility and molar conductivity measure-
ments, it is possible to draw up the proposed structures of the
complexes as shown in Fig. 2. The in vitro antibacterial and antifun-
[
29] D.S. Lee, H.J. Han, K. Kim, W.B. Park, J.K. Cho, J.H. Kim, J. Pharm. Biomed. Anal.
2 (1994) 157–164.
30] J. Sulkowsha, R. Staroscik, Pharmazie 30 (1975) 405–408.
1
[
[31] G.G. Mohamed, N.E.A. El-Gamel, Spectrochim. Acta A 60 (2004) 3141–3154.
[32] A.D. Taneja, K.P. Srivastova, J. Inorg. Nucl. Chem. 33 (1971) 2678–2680.
[33] R.G. Anderson, G. Nickless, Anal. Chim. Acta 39 (1967) 469–477.
[34] (a) H. Irving, R.J.P. Williams, Nature 162 (1948) 746–747;
(b) H. Irving, R.J.P. Williams, J. Chem. Soc. (1953) 3192–3210.